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Background: Frequent exacerbations induce a high burden to Chronic Obstructive Pulmonary Disease (COPD). We
investigated the course of exacerbations in the published COSMIC study that investigated the effects of 1-year
withdrawal of fluticasone after a 3-month run-in treatment period with salmeterol/fluticasone in patients with
COPD.
Methods: In 373 patients, we evaluated diary cards for symptoms, Peak Expiratory Flow (PEF), and salbutamol use
and assessed their course during exacerbations.
Results: There were 492 exacerbations in 224 patients. The level of symptoms of cough, sputum, dyspnea and
nocturnal awakening steadily increased from 2 weeks prior to exacerbation, with a sharp rise during the last week.
Symptoms of cough, sputum, and dyspnea reverted to baseline values at different rates (after 4, 4, and 7 weeks
respectively), whereas symptoms of nocturnal awakening were still increased after eight weeks. The course of
symptoms was similar around a first and second exacerbation. Increases in symptoms and salbutamol use and
decreases in PEF were associated with a higher risk to develop an exacerbation, but with moderate predictive
values, the areas under the receiver operating curves ranging from 0.63 to 0.70.
Conclusions: Exacerbations of COPD are associated with increased symptoms that persist for weeks and the course
is very similar between a first and second exacerbation. COPD exacerbations are preceded by increased symptoms
and salbutamol use and lower PEF, yet predictive values are too low to warrant daily use in clinical practice.
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Goals in the management COPD are to prevent and
control symptoms, to reduce the frequency and severity
of exacerbations, and to improve health status and exer-
cise tolerance and prevent disease progression [1]. In par-
ticular, frequent exacerbations induce a high economic,
social, and personal burden. Exacerbations are regarded
as important to disease prognosis, since an increased* Correspondence: m.van.den.berge@umcg.nl
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distribution, and reproduction in any mediumfrequency of these episodes has been reported to be asso-
ciated with accelerated lung function decline and increa-
sed mortality rates, particularly if these require admission
to hospital [2-4].
Studies in asthma have shown that exacerbations resolve
generally within 2 weeks with respect to symptoms, salbu-
tamol use and peak expiratory flow (PEF) values [5]. Data
on exacerbations in COPD are still rather scarce [6-9],
one study suggesting that symptoms resolve within two
weeks just as in asthma [7], though another post hoc ana-
lysis in a large group of COPD patients suggests that this
would take longer [10]. A better understanding of the
course of symptoms around COPD exacerbations is im-
portant. It may help to optimize the duration of treatmentCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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recognition of symptoms and signs that predict a pending
COPD exacerbation will enable physicians to start treat-
ment in an early phase.
According to the GOLD (Global Obstructive Lung
Disease) guidelines, the goals of clinical control in patients
with COPD include both health status (improved exer-
cise tolerance and emotional function) and clinical goals
(prevention of disease progression and minimization of
symptoms). The Clinical COPD questionnaire (CCQ) is
the first practical instrument to be used for routine evalu-
ation of clinical control concerning patients with COPD
in general practice [11,12]. A worse health status may con-
tribute to hospitalisations [13], yet this has not been repor-
ted for CCQ so far.
In a previous report on the COSMIC (COPD and
Seretide: a Multi-Center Intervention and Characterization)
population with moderate to severe COPD, it has been
shown that there are no significant differences with respect
to the number of moderate to severe exacerbations expe-
rienced by patients in whom inhaled steroids were with-
drawn after a run-in period with fixed dose of fluticasone
(500 μg) and salmeterol (50 μg), versus those who continued
this treatment [14]. Only the number of mild exacerbations
(defined as increased need for rescue medication above the
run-in period) was significantly larger in the group in which
inhaled steroids were withdrawn.
The current report explores which factors determine
the course of moderate and severe exacerbations, i.e. the
duration and resolution of an exacerbation in relation to
symptoms, additional use of beta-agonists and peak ex-
piratory flow (PEF) in this group of COPD patients. It
furthermore assesses the similarity of the course of sym-
ptoms around a first and second exacerbation. Informa-
tion on the intra-individual variability of the course of
symptoms around an exacerbation is important, since we
wished to assess whether a change in symptoms can pre-
dict the occurrence of a moderate or a severe COPD
exacerbation.
Methods
Patients and study design
Inclusion and exclusion criteria, methods for lung func-
tion measurements and design of the COSMIC study
have been reported previously [14]. In short, all patients
were diagnosed with COPD according to the current
GOLD guidelines and were selected based on the occur-
rence of at least 2 exacerbations in the year preceding
entry to the study [1]. During a three-month run-in
period, all patients received combined salmeterol 50 μg
and fluticasone 500 μg (SeretideW or AdvairW 50/500 μg)
twice daily. Thereafter, patients were randomized to a
12-month treatment with either salmeterol/fluticasone
or salmeterol alone [14]. We obtained approval from allethics committees at each participating site, and all
patients provided written informed consent.
Exacerbations and rescue medication use
Patients recorded use of rescue medication (salbutamol)
over the last 24 hours in daily paper record cards. If the
patient’s condition worsened and a course of oral corti-
costeroids (standardized course of prednisolone tablets
30 mg/day for 10 days; at the discretion of the physician
accompanied by a 10-day course of antibiotics) was indi-
cated based on the judgment of the research physician
or general practitioner, the exacerbation was defined as
moderate. If hospitalization was required at the discre-
tion of the clinician, the exacerbation was considered se-
vere. The time of onset and end of exacerbation was
based on clinical judgment according to the research
physician at each site.
Daily record cards and morning PEF
Every morning patients recorded severity scores of symp-
toms over the previous 24 hours on shortness of breath,
cough, sputum production and night-time sleep distur-
bance (breathlessness 0 (none) to 4 (breathless at rest);
cough and sputum production 0 (none) to 3 (severe); night-
time sleep disturbance due to respiratory symptoms 0
(none) to 4 (did not sleep at all). Patients recorded their
daily morning PEF throughout the run-in and the treat-
ment period, prior to the inhalation of COPD (study) medi-
cation. The highest of three values was used for analysis.
Health status
The Clinical COPD Questionnaire (CCQ) was administe-
red to assess health status, a higher score meaning greater
impairment. It is a 10-item, self administered question-
naire that can be completed in less than 2 minutes. Items
are divided into three domains: symptom, functional state
and mental state. Patients are required to respond to each
item on a seven-point Likert scale where 0= asymptom-
atic/no limitation and 6 = extremely symptomatic/total
limitation. The final score in the mean of all ten items and
scores for the three domains can be calculated separately
if required.
Statistical analysis
Poisson-regression was used to evaluate the relation bet-
ween the annual exacerbation rate and the factors FEV1
(%predicted), age, gender, smoking status and CCQ.
Mixed model Anova (SAS PROC MIXED) was used to
evaluate associations between these factors and the log-
transformed durations of both the moderate and severe
exacerbations. Profiles of all longitudinal diary card data
were used to characterize exacerbations. Only patients
with a proper scoring of diaries in each of both periods
were evaluated in these analyses, i.e. at least 50 percent of
van den Berge et al. Respiratory Research 2012, 13:44 Page 3 of 9
http://respiratory-research.com/content/13/1/44diary days. In addition patients were required not to have
a new exacerbation in the 8-week period after the onset
of the exacerbation. We analyzed the diary card data
to investigate whether the increase in total or separate
symptom scores could predict the occurrence of an ex-
acerbation at each day of follow-up as follows. The in-
crease of the mean symptom score was calculated for each
patient separately during the week before the day of onset
of the exacerbation, i.e. days 1 to −6, as compared to the
mean symptom score during the week covering days −8 to
−14. These increases were calculated for all patients du-
ring each day of follow-up, irrespective of whether the pa-
tient had experienced an exacerbation or not. So in fact a
time-window of 14 days width of 2 successive weeks is
used and this window is moved one day along time step
by step, resulting at each step in a difference of 2 moving
averages of symptom scores. For example, if a patient has
a mean score of 10 points during days 101 to 107 and this
was 13 points during days 108 to 114, then the value of
the calculated increase at day 115 equals +3 points. The
information at all follow-up days can be combined using
Cox-regression, with the calculated increases of symptom
scores per patient at each day of follow-up as a time-
dependent covariate. With this method, the daily risk of
an exacerbation is quantified in relation to the observed
longitudinal changes in symptom scores. Regarding pre-
diction of an exacerbation, only data to the first exacer-
bation were analyzed. The same method with moving
averages was used to investigate the predictive value
of changes in daily PEF measurements and salbutamol
use. Receiver operating characteristic curves (ROC-curves)
were constructed to evaluate the predictive value of the
changes in total or separate symptom scores, PEF or salbu-
tamol use as explained above. An area under the Receiver
Operating Curve (AUC) of 0.8 or greater is generally con-
sidered to indicate a good predictor. A two-sided p-value
below 0.05 was considered to be significant in all analyses.Table 1 Demographic data and baseline characteristics of ran
Salmeterol n=184
Age, years 64.0
Male 137
Current smoker 64
Pack-years smoked 37.8
Prebronchodilator FEV1 % predicted* 48.2
Reversibility, % predicted FEV1* 4.9
CCQ Total score * 1.7
CCQ functional 1.7
CCQ emotional 0.5
CCQ symptoms 2.3
* at randomization. FEV1: forced expiratory volume in one second. Data are present
Reversibility was assessed by inhaling 400μg salbutamol using a VolumaticW spacerResults
Baseline characteristics of the 373 patients enrolled are
presented in Table 1. Follow-up in the salmeterol and
salmeterol/fluticasone group amounted to 161 and 179
person-years respectively. During this period, 109 patients
in the salmeterol group experienced a total of 254 exa-
cerbations, 19 being severe. In the salmeterol/fluticasone
group, 115 patients had a total of 238 exacerbations, 24
being severe. Poisson regression analysis, allowing for
treatment, gender, age, baseline FEV1 % predicted and
smoking status, showed that the annual moderate to
severe exacerbation rate was 1.6 per patient year in
the salmeterol group and 1.3 per patient year in the
salmeterol/fluticasone group (1.2-fold greater with
salmeterol, 95% confidence interval ((CI): 0.9-1.5; p=0.15).
When considering moderate and severe exacerbations
separately, no significant difference was observed between
the treatment arms as well.
Duration of exacerbation
There were 492 moderate or severe exacerbations in a
total of 224 COPD patients, median duration of these
492 exacerbations being 10 days (range 2–119 days).
The duration of a severe exacerbation was on average
46% longer than a moderate one (geometric mean 18.6
and 11.5 days respectively, p=0.001); no significant dif-
ferences existed between the treatment arms. Mixed
model Anova, allowing for gender, age, current and pack-
years smoking, treatment and FEV1 % predicted, showed
that the number of pack-years smoking was the only sig-
nificant predictor for the duration of a severe exacerba-
tion. With every 5 pack-years smoking, the mean duration
of a severe exacerbation increased 1.15 times. There
were no significant effects of any of these parameters
on the duration of a moderate exacerbation. Furthermore,
the CCQ total score at baseline did not significantly
contribute to the duration of moderate and/or severedomized patients
Salmeterol + Fluticasone n=189
(7.7) 63.0 (7.9)
(75) 138 (73)
(35) 74 (39)
(18.1) 34.8 (17.4)
(12.9) 47.4 (13.9)
(4.1) 4.7 (3.5)
(0.9) 1.6 (0.8)
(1.1) 1.7 (1.0)
(0.9) 0.5 (0.8)
(1.1) 2.1 (0.9)
ed as number (%) or mean (SD). CCQ= Control of COPD Questionnaire;
.
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of CCQ.
Course of symptoms, PEF and salbutamol use before and
after the first moderate or severe exacerbation
Of the 224 patients who experienced an exacerbation,
48 were labeled as treatment failures and excluded from
further analyses as they suffered from a new exacerba-
tion within 8 weeks after the onset of the first exacerba-
tion. Of the remaining 176 patients, 39 were excluded
from analysis because they did not properly fill in their
diary cards for more than 50% of the days. Thus, we
were able to analyze the course of symptoms around a
first moderate or severe exacerbation in 137 patients. Of
these 137 patients, 101 were treated with a course of oral
prednisolone and antibiotics, whereas 36 patients were
treated with oral prednisolone alone. Figure 1 shows the
marked similarity in profile of the four different symptom
scores. The mean level of symptoms before an exacerba-
tion steadily increased from 2 weeks prior to exacerbation,
with a sharp rise during the last week. After the first mod-
erate or severe exacerbation, mean symptom scores were
significantly higher than the level during stable disease,
i.e. the fourth week before that particular exacerbation.
Weekly average symptom scores at two weeks after an ex-
acerbation were generally not back to the average level
present during the fourth week prior to that exacerbation.
When analyzing the weekly average of salbutamol use andFigure 1 Mean symptom scores (with SEM) from diary for
shortness of breath (shbr), (scale 0–4), sputum (scale 0–3),
cough (scale 0–3) and night-time sleep disturbance (scale 0–4)
according to day number before and after the onset (day 0) of
the first exacerbation. Evaluated patients had to contribute at least
50% of properly scored diary days in the 4 weeks period before the
onset. The same applied to the 8 weeks period after the onset. In
addition no new exacerbations had to occur within the latter 8
weeks period, leaving n=137 patients for analysis for all curves.
Recovery from an exacerbation is slowest with shortness of breath,
followed by nocturnal respiratory symptoms, sputum, and cough.each individual symptom separately, mean salbutamol use
and shortness of breath score were still significantly higher
during the 6th and 7th week after the exacerbation respec-
tively compared to the weekly average scores during stable
disease, i.e. the fourth week prior to the onset of the
exacerbation (Table 2). With mean weekly sputum and
cough scores, this took 4 weeks, whereas mean weekly
night-time awakening scores due to respiratory symptoms
lingered on for even longer, i.e. they were still significantly
higher than at baseline by 5 weeks with borderline signi-
ficance thereafter and again a significantly higher score
at 8 weeks after an exacerbation. Mean weekly PEF
values were back to pre-exacerbation levels within 2 weeks
(Table 2). When analyzing the course of symptoms bet-
ween patients with and without antibiotics, similar results
were obtained.
Similarity between a first and second exacerbation
Figure 2 shows that the mean course of the increase and
decrease in symptoms was very similar around the onset
of a first and second moderate exacerbation. The mean
value in the period from day −28 to day 0 did not signifi-
cantly differ between the 1st and 2nd moderate exacerba-
tion. The same applied to the period from day 1 to day
56 after the start of the exacerbation. In the period be-
fore the exacerbation, mean values of total symptom
scores were higher for the severe exacerbation as com-
pared to the first and second moderate exacerbations
(both p<0.02), the pattern being similar for separate
symptoms of cough, sputum, shortness of breath and
night-time awakening (Figure 3). Similarly, salbutamol
use was significantly higher in the period before the
onset of a severe exacerbation and PEF values were sig-
nificantly lower.
Prediction of exacerbation by symptoms preceding the
first moderate or severe exacerbation
We reported previously [14] that females had a 1.4-fold
higher exacerbation rate than males (p=0.03) and that
baseline FEV1 % predicted strongly associated with the ex-
acerbation rate, i.e. each 10 points lower value of FEV1 %
predicted led to a 1.2-fold increase in exacerbation rate
(p<0.001). Adding baseline CCQ values to this Poisson re-
gression model showed that the CCQ significantly con-
tributed to the exacerbation rate. When adding each
domain (i.e. Symptoms, Mental and Functional), the func-
tional domain remained in the Poisson-model with a
highly significant contribution (p=0.001). The factor gen-
der became of borderline significance (p=0.08), whereas
FEV1 % predicted remained significant (p=0.019).
The averages of the symptom scores in two subsequent
weeks were compared to assess whether an exacerbation
is pending. Although there were individuals who had a
marked increase in symptoms during the week preceding
Table 2 The average symptoms scores, PEF values and number of puffs of salbutamol use are presented, starting from
4 weeks prior until 8 weeks after the onset of exacerbation
Wk-4 Wk1 Wk2 Wk3 Wk4 Wk5 Wk6 Wk7 Wk8
Shortness of breath 1.5(.1) 2.0(.1) 1.8(.1) 1.7(.1) 1.7(.1) 1.7(.1) 1.6(.1) 1.6(.1) 1.6(.1)
* * * * * ns p=.047 ns
Cough 1.1(.1) 1.7(.1) 1.3(.1) 1.2(.1) 1.1(.1) 1.0(.1) 1.0(.1) 1.1(.1) 1.1(.1)
* * * ns ns ns ns ns
Sputum 1.1(.1) 1.7(.1) 1.4(.1) 1.2(.1) 1.2(.1) 1.2(.1) 1.1(.1) 1.1(.1) 1.1(.1)
* * * ns ns ns ns ns
Nocturnal wakening 0.3(.1) 0.9(.1) 0.5(.1) 0.5(.1) 0.4(.1) 0.5(.1) 0.4(.1) 0.4(.1) 0.4(.1)*
* * * * * ns p=.06 p=.04
PEF, l/min 279(8) 264(7) 275(8) 276(8) 277(8) 277(8) 278(8) 277(8) 273(7)
* ns ns ns ns ns ns ns
Salbutamol , puffs/day 1.5(.2) 2.1(.2) 1.8(.2) 1.7(.2) 1.7(.2) 1.7(.2) 1.8(.2) 1.7(.2) 1.7(.2)
* * * * * * ns ns
Data given are mean values, with standard errors between parentheses (repeated measurements Anova estimates). A particular week for a patient was considered
evaluable if there were at least 4 valid diary days during that week.
* p<0.05 for the comparison with Wk-4.
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served (Figure 4). Table 3 shows that a change in total
symptom score in two subsequent weeks by 1–2 points
increased the risk of a moderate to severe exacerbation 4.8
fold, and 8.2 fold when there was an increase of 2–3
points. When assessing the sensitivity and specificity of
the change in total symptom score using ROC-curves, the
area under the curve (AUC) obtained was 0.70 (Figure 5).
AUC values for the separate symptoms were slightly
lower: 0.61 for shortness of breath, 0.67 for cough, 0.64
for sputum and 0.63 for nocturnal respiratory symptoms.Figure 2 Mean total symptom scores (with SEM) from diary
cards according to day number before (days −28 to 0) and
after (days 1 to 56) the onset of an exacerbation. Day 0 marks
the recorded day of the onset of an exacerbation in the clinical
record form. Circles, squares and triangles denote the 1st moderate,
2nd moderate and 1st severe exacerbation, respectively. Outcomes
for the 1st severe exacerbation are graphed only up to the day of
onset because of many missing values after its onset (when patient
were admitted to the hospital).A similar analysis for the two-week changes in PEF and
daily salbutamol use resulted in AUC values of 0.67 and
0.63, respectively. We were unable to perform the above
analyses for only severe exacerbations, because of too low
numbers.
Discussion
Our study shows that exacerbations of COPD are asso-
ciated with increased symptoms that persist for weeks.
Especially shortness of breath and nocturnal awakening
due to respiratory symptoms persist for many weeks
after the resolution of the acute phase of an exacerbation
(7 and 8 weeks respectively). In addition, we demons-
trate that the course of symptoms is very similar bet-
ween a first and second exacerbation. Finally, we show
that exacerbations are preceded by lower functional sta-
tus, increased symptoms and salbutamol use and lower
PEF yet predictive values are too low to warrant their
use for clinical practice.
This is in contrast to observations in asthma where
symptoms during an exacerbation remit within 7–10 days
after treatment with prednisone [5]. Especially shortness
of breath and nocturnal awakening due to respiratory
symptoms persist for many weeks after the resolution of
the acute phase of an exacerbation (7 and 8 weeks respect-
ively). Seemungal and coworkers [8,9] have previously
investigated the course of an exacerbation in a cohort of
101 patients with COPD, who had a similar disease seve-
rity as our group of 373 patients. They focused on the
change in lung function (PEF, FEV1 and FVC) and found
that there was only a limited fall in lung function during
an exacerbation, compatible with our findings. Additio-
nally, they followed the course of an exacerbation with
diary cards and reported that the median time to recovery
Figure 3 Mean symptom scores (with SEM) for A) Cough, B) Sputum, C) Shortness of breath, and D) Night-time awakening. Based on
diary cards according to day number before (days −28 to 0) and after (days 1 to 56) the onset of an exacerbation. Day 0 marks the recorded day
of the onset of an exacerbation in the clinical record form. Circles, squares and triangles denote the 1st moderate, 2nd moderate and 1st severe
exacerbation, respectively. Outcomes for the 1st severe exacerbation are graphed only up to the day of onset because of many missing values
after its onset (when patients were admitted to the hospital).
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to 14 days. However, the study did not report on the
course of individual symptoms. In that respect our fin-
dings are new and show that some symptoms remit more
rapidly than others. Nocturnal awakening due to respira-
tory symptoms was especially lingering on for many weeks
after an exacerbation. This is in agreement with the fin-
dings by Partridge and colleagues that COPD patients in-
dicate the morning as the time when their symptoms are
most severe [15]. Whether this reflects some level of car-
diac insufficiency is not yet clear. Alternatively, it might
reflect a worse impact of ongoing inflammation in the air-
ways at the time that the autonomic nervous imbalance is
largest [16]. This clearly needs further study.
Interestingly, the mean course of the increase and de-
crease in symptoms around the onset of a moderate ex-
acerbation was very similar at the first and the second
exacerbation. It thus appears that, despite a large inter-
individual difference in the course of an exacerbation,
the overall course of a first and second moderate exacer-
bation is quite similar in one and the same individual.
As one can anticipate, the mean values of symptom scoreswere higher in the period before a severe exacerbation
than before the first and second moderate exacerbations.
Similarly, salbutamol use was significantly higher in the
period before onset of a severe exacerbation and PEF
values were significantly lower. Unfortunately, we had in-
sufficient numbers of patients to compare the course of a
severe and moderate exacerbation within the same indivi-
duals. It remains to be clarified which factors determine a
severe exacerbation that requires hospitalization and one
that can be managed in the home situation. It may well
be, as Donaldson and coworkers suggested [2] that se-
vere exacerbations occur rather in patients with more
longstanding COPD, hence the low numbers of patients
with both a severe and moderate exacerbation in our
study.
We sought for factors in diary cards that would predict
an exacerbation in the near future. With each increase
in total and separate symptom scores or salbutamol use
per week, or decrease in PEF the risk of an exacerbation
increased. Although the relative risks were high with
weekly increases in reports, the overall predictive value
of these changes was still rather limited in view of the
Figure 4 Graph of increases in moving weekly averages for the different symptom scores from the diaries at each day during follow-up.
Triangles represent individual values of the increase at the day of a patient’s (first) exacerbation. The gray area represents the reference range at
each day of follow-up, i.e. mean +/− 2 SD values of the increase for those who did not have an exacerbation at the days indicated.
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ever cut-off level one chooses for the increase of the
various parameters, the rate of false positive findings
remains high and therefore the specificity is low for ac-
ceptable values of the sensitivity (Figure 5). The latter
suggests that writing down symptoms, salbutamol use or
PEF values in reports on a daily basis does not help to
assess the risk for an exacerbation on an individual
basis.Table 3 Cox-regression analysis of change in average
points in total symptoms in two subsequent weeks
(maximum score in total symptoms = 14) as risk for a
moderate or severe exacerbation
Change in points Relative
Risk (RR)
p- value 95% Confidence
Interval for RR
<1 point 1# -
1-2 points 4.8 <0.001 3.1 - 7.5
2-3 points 8.2 <0.001 4.3 – 15.8
>3 points 18.7 <0.001 10.5 – 33.4
# reference category.
Figure 5 ROC-curve depicting Sensitivity versus False positive
rate, i.e. 1-specificity, of change in total symptom score per
week to predict a moderate or severe exacerbation. Area under
curve = 0.70. Dotted diagonal line represents an imaginary test
without any predictive value.
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quent exacerbators showed that those with frequent
exacerbations had a faster decline in FEV1 [2]. Moreover,
frequent exacerbations are associated with reduced qua-
lity of life and daily activities [8,17]. In light of the effect
of frequent exacerbations on progression of COPD, our
findings also emphasize the importance of preventing
COPD exacerbations and particularly to detect patients
who are at risk of frequent exacerbations in order to
open avenues for reduction in disease progression. Thus,
we tried to assess which factors predict that an indi-
vidual is prone to frequent exacerbations of COPD. As
expected, we found a lower FEV1 %predicted to be asso-
ciated with an increased number of exacerbations, a
finding compatible with data in the literature [2,17]. In-
terestingly, and a new observation, the control of COPD
questionnaire was associated with the number of exacer-
bations in patients with moderate to severe COPD as well.
In particular, a worse functional status of this domain was
associated with frequent exacerbations.
There are some limitations to our study. First, there
were relatively few severe exacerbations, probably reflec-
ting the fact that patients were treated and followed accur-
ately in a randomized controlled trial which may have
influenced our results. In addition, we cannot rule out the
possibility that regular treatment with salmeterol with or
without added fluticasone, may have blunted the changes
in PEF which recovered very quickly after a COPD exacer-
bation, whereas this as not the case for the perception of
symptoms.
In conclusion, this prospective study in moderate to
severe COPD patients shows that symptoms persist for
several weeks after an exacerbation, suggesting that the
underlying pathophysiology is not resolved with a two-
week course of oral corticosteroids and/or antibiotics.
This may have implications for a better understanding
why exacerbations, which may have a systemic effect on
COPD as well, may affect the outcome of COPD. In
addition, we show that the course of symptoms is very
similar around a first and second exacerbation. Finally,
COPD exacerbations can be predicted by an increase in
respiratory symptoms, salbutamol use and decrease in
PEF, yet the predictive values of these parameters are
too low to warrant their daily use in clinical practice.
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